about
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challengesAntitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts.The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts.Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemiaHow do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?
P50
Q26866236-09C5EC2D-2A09-4E52-B628-821D3A625A6EQ34223860-2427A4FD-7A89-4A1E-B07B-0CB896F43773Q38783302-C97E2799-AD5A-4AE8-9914-E7C742E51A26Q48738476-89B6094E-41CC-497A-9DA6-CFCEBF594ECCQ50054520-5F34AB97-AC33-41C6-9EFA-189DA989B3D2Q87869524-B8D37FFC-5C95-4F49-AEB2-7A392443139EQ88063526-2B251649-CEAE-48EC-BB6B-4F6363890D2B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Vela
@ast
Maria Vela
@en
Maria Vela
@es
Maria Vela
@nl
type
label
Maria Vela
@ast
Maria Vela
@en
Maria Vela
@es
Maria Vela
@nl
prefLabel
Maria Vela
@ast
Maria Vela
@en
Maria Vela
@es
Maria Vela
@nl
P106
P31
P496
0000-0001-6956-6297